The benefits of tamoxifen to prevent breast cancer outweigh its side effects in postmenopausal women under 55 who are at increased risk of developing the disease, according to a company Archimedes Inc. in San Francisco (United States), published in the journal "Cancer".
Research shows that tamoxifen may protect against breast cancer for years after treatment ends, however, is difficult to identify women who could benefit most from treatment. Side effects of the drug can include pulmonary embolism, endometrial cancer, deep vein thrombosis and cataracts, as well as hot flashes and early menopause.
The scientists, led by Peter Alperin, Buy Triactol used a mathematical model to simulate a population of postmenopausal women younger than 55 years in a virtual clinical trial that compared tamoxifen with no treatment. The authors established the model of tamoxifen therapy based on an analysis of four trials evaluating cancer prevention and treatment effects 10 years after you finish taking it. And they took information on the incidence and survival of the main register of cancer.
The researchers found that in postmenopausal women 55 years and younger with a 5-year risk of developing breast cancer of 1.66 percent or higher, the benefits of tamoxifen are maximized while its side effects are minimized.
Alperin concluded that in this group of women, the use of tamoxifen to prevent breast cancer could save lives and have a low frequency of side effects.

